Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully FiledRichmond, Virginia, March 17, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a U.S.-based certified B ...

Hamilton Beach Brands sees revenue growth to $654.7M in 2024, bolstered by acquisitions and cost cuts. Read why HBB stock ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Humanetics' Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) L ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical ...

WM sees future healthcare trends, such as the growth of at-home healthcare, as a future business opportunity as it works to ...

Shilpa Medicare has launched its new full service ‘hybrid’ CDMO at DCAT 2025. The newly formed CDMO will see Shilpa serve both small and large molecules customers as well as peptides – with oncology a ...

Fintel reports that on March 17, 2025, D. Boral Capital initiated coverage of Plus Therapeutics (NasdaqCM:PSTV) with a Buy recommendation. Analyst Price Forecast Suggests 1,440.22% Upside As of March ...